A multi-center double blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis. Protocol Number: EFC10531, Version #1 (Electronic 2.0) dated 3 July 2008. Investigator's Brochure Edition 11 dated 28 June 2007.,
Role: Investigator,
Sanofi-Aventis U.S., Inc.,
(04/2012 - 04/2013)
Status: Completed
A 6-month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of fingolimod 0.5 mg/day in patients with relapsing forms of multiple sclerosis who are candidates for MS therapy change from previous disease modifying therapy (EPOC). Protocol number: CFTY720DUS01, version V01, dated 26OCT2010. Informed consent version 1, dated 08/05/10. Investigator's brochure ed. 12 (22Feb2010). Package inserts: avonex dry powder, avonex leuer lock, betaseron, copaxone, extavia, rebif.,
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(12/2011 - 12/2012)
Status: Completed
A randomized, multicenter, placebo-controlled and active reference (glatiramer acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis. Protocol number: 109MS302, version 2 dated 23 March 2007. Informed consent form version 4, dated 18 April 2007. Investigator's Brochure version 4, dated 28 August2006 and Addendum 1, dated 05 February 2007.,
Role: Investigator,
Biogen, Inc.,
(05/2011 - 05/2012)
Status: Completed